Sino Biological - Custom Protein Production Services
Revvity Signals || Signals One™

EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 1

    ABM Pharma Tactics US: Unlocking B2B Lead Gen Success

    Kate Williamson

    The Account-based marketing (ABM) pharma strategies are reshaping the US B2B pharma marketing by focusing the high value accounts rather than the lead volume. Pharmaceutical account-based marketing en...

  • 3

    Advances in mRNA Therapeutics and Vaccines

    Prince Kumar Lat

    The ability to precisely target specific cells and deliver therapeutic payloads to their “site-of- action” has made mRNA a particularly attractive approach for personalized medicine. Recen...

press releasesRead more...

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Inc a clinicalstage targeted oncology company committed to developing firstinclass and bestinclass targeted cancer therapies today announced that the European Medicines Agency EMA has validated the Marketing Authorization Application MAA for varegacestat an investigational oral oncedaily ga...

ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis

Sun Pharmaceutical Industries Limited Reuters SUNBO Bloomberg SUNP IN NSE SUNPHARMA BSE Sun Pharma and includes its subsidiaries andor associated companies announced today that the US Food and Drug Administration FDA has approved the supplemental Biologics License Application

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

Eloxx Pharmaceuticals Inc a clinicalstage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases today announced that the US Food and Drug Administration FDA has cleared the Companys Investigational New Drug IND application for exaluren for the treatment of nonsensem...

BioTalent Canada Launches BioReady Ontario to Connect AI Skills With Biomanufacturing Careers

BioTalent Canada is launching a new program BioReady Ontario to address two interconnected challenges affecting Ontarios bioeconomy building a skilled workforce and the adoption of emerging technologies like AI BioTalent Canadas labour market study projected that Canadas bioeconomy would require a...

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

04 - 05

Nov 2026

Advanced Therapies USA

Hynes Convention Center, Bosto...

05 - 05

Nov 2026

PDA Contamination Control Strategy Workshop

Sheraton Grand Incheon Hotel,...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

LATEST NEWSRead more...

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

Denali Therapeutics Inc announced that AVLAYAH tividenofusp alfaeknm has been recognized as the Best Biotechnology Product of by The Galien Foundation AVLAYAH is the first biologic approved by the US Food and Drug Administration FDA that is specifically designed to cross the bloodbrain barrier and...

Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors

Doximity Inc the leading digital platform for US medical professionals has launched DoseCheck a free additional safety layer in Doximity Ask that instantly checks every AIgenerated medication dosing claim against a structured drug database to reduce treatment

Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

Celularity Inc a longevityfocused regenerative and cellular medicine company and Vesalius Longevity Labs Inc Vesalius a leading global peptide and longevity brand today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated firstofitskind US final stage

Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

Rakovina Therapeutics Inc a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery and Bostonbased Celvion Therapeutics Celvion today announced the completion of the first analysis in their collaboration using Celvions EMphora

Manta Cares and Cancer Support Community SF Bay Area Partner to Bring AI-Powered Cancer Support to Northern California Patients and Families

Manta Cares a San Francisco company that builds AI for people with cancer and their families and Cancer Support Community San Francisco Bay Area CSC SFBA which has offered free support to people affected by cancer since today announced a partnership to offer a new level of support for people

Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)

Onco the nations leading independent Specialty Pharmacy has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy sunvozertinib which is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC with epidermal...